company background image
INNP.F logo

InnoCan Pharma OTCPK:INNP.F Stock Report

Last Price

US$0.16

Market Cap

US$36.9m

7D

0%

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials

InnoCan Pharma Corporation

OTCPK:INNP.F Stock Report

Market Cap: US$36.9m

INNP.F Stock Overview

A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. More details

INNP.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

InnoCan Pharma Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for InnoCan Pharma
Historical stock prices
Current Share PriceCA$0.16
52 Week HighCA$0.24
52 Week LowCA$0.091
Beta2.92
1 Month Change7.10%
3 Month Changen/a
1 Year Changen/a
3 Year Change-71.85%
5 Year Changen/a
Change since IPO-18.63%

Recent News & Updates

Recent updates

Shareholder Returns

INNP.FUS PharmaceuticalsUS Market
7D0%-0.3%-2.7%
1Yn/a7.9%23.4%

Return vs Industry: Insufficient data to determine how INNP.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how INNP.F performed against the US Market.

Price Volatility

Is INNP.F's price volatile compared to industry and market?
INNP.F volatility
INNP.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: INNP.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine INNP.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018n/aIris Bincovichinnocanpharma.com

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.

InnoCan Pharma Corporation Fundamentals Summary

How do InnoCan Pharma's earnings and revenue compare to its market cap?
INNP.F fundamental statistics
Market capUS$36.94m
Earnings (TTM)-US$2.60m
Revenue (TTM)US$28.93m

1.3x

P/S Ratio

-14.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INNP.F income statement (TTM)
RevenueUS$28.93m
Cost of RevenueUS$2.86m
Gross ProfitUS$26.07m
Other ExpensesUS$28.67m
Earnings-US$2.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0091
Gross Margin90.11%
Net Profit Margin-9.00%
Debt/Equity Ratio0%

How did INNP.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:50
End of Day Share Price 2024/12/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution